产品展示更多>>
- Splitomicin 5690-03-9
- Splitomicin 5690-03-9
Splitomicin 5690-03-9
产品描述 描述 Splitomicin is a selective NAD(+)-dependent histone deacetylase Sir2p inhibitor with IC50 of 60 μM, showing a higher activity in a cell-based assay.
纯度 ＞98%储存/保存方法 Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.基本信息 别名 斯普利特麻一辛外观 Powder可溶性/溶解性 DMSO : 19.8 mg/mL (100 mM)
Ethanol : 19.8 mg/mL (100 mM)生物活性 靶点 Sir2pIn vitro(体外研究) Splitomicin inhibits Sir2p deacetylase activity by altering or blocking access to the acetylated histone binding pocket. [1] Splitomicin inhibits platelet aggregation induced by thrombin, collagen, AA and U46619 via inhibition of cyclic AMP phosphodiesterase activity and subsequent inhibition of intracellular Ca(++) mobilization, TXB2 formation and ATP release.In vivo(体内研究) In a photochemical injury mouse model, splitomicin (80 mg/kg/d i.p.) enhances tissue factor activity in the arterial vessel wall and promotes carotid artery thrombus formation.参考文献 参考文献 1. Bedalov A, et al. Proc Natl Acad Sci U S A. 2001, 98(26), 15113-15118.
2. Liu FC, et al. Thromb Res. 2009, 124(2), 199-207.
研究领域 研究领域 CancerCancer MetabolismCancerTumor biomarkersDrug DiscoverySmall Molecule DrugLead Compound DiscoverySplitomicin 5690-03-9温馨提示：本产品仅作科研实验使用，不支持临床等研究